Improving stem cell mobilization strategies: future directions

Bensinger, William I.; DiPersio, John F.; McCarty, John M.

doi:10.1038/bmt.2008.410

Cited by 202 publications

(216 citation statements)

References 133 publications

(253 reference statements)

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…In general CT plus G-CSF mobilizes 2-3 times more CD34 þ cells than G-CSF alone, 74 although there may be no major differences between these approaches in the subgroup of patients who are hard-to-mobilize. 75 On the basis of two phase III studies, 15,76 a combination of plerixafor and G-CSF is more efficient than G-CSF alone for mobilization of stem cells in MM and NHL patients.…”

Section: Effect Of Mobilization Regimen On Graft Characteristicsmentioning

confidence: 99%

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

Jantunen

Früehauf

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Effect Of Mobilization Regimen On Graft Characteristicsmentioning

confidence: 99%

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

Jantunen

Früehauf

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The haematopoietic niche of the bone marrow expresses a broad array of cell surface receptors, such as the CXC chemokine receptors CXCR4 and CXCR2, lymphocyte functionassociated antigen 1, very late antigen 4 and glycoprotein CD44, among others. 65 Data from a number of preclinical models showed that the inhibition of these receptor-ligand interactions resulted in enhanced progenitor cell mobilisation. [66][67][68] Among them, CXCL12/ CXCR4 interactions may play key role in the regulation of the routine and active egress of progenitor and maturing cells from the marrow into the blood.…”

Section: Trafficking Of Exogenously Administered Stem Cellsmentioning

confidence: 99%

“…Another common mobilisation strategy in current clinical applications includes the use of cytokines alone or in conjunction with chemotherapy. 65 The currently available cytokines include granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin and recombinant methionyl human stem cell factor. 65 …”

Section: Trafficking Of Exogenously Administered Stem Cellsmentioning

confidence: 99%

Stem cells: novel players in the treatment of erectile dysfunction

Zhang¹,

Albersen²,

Jin³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

“…36 No significant advantage has been reported with a CD34+ cell dose higher than 2 × 10 6 CD34+ cells/kg regarding PMN recovery while a significantly slower platelet recovery has been observed when compared with doses higher than 5 × 10 6 CD34+ cells/kg. [36][37][38][39][40][41] According to the current literature, [42][43][44] expert panel agreed to define a graft content of ⩾ 2 × 10 6 CD34+ cells/kg as the standard minimal dose. Moreover, a higher number of CD34+ cells (for example, 3-5 × 10 6 /kg) was considered the ideal to minimize the risk of delayed engraftment.…”

Section: Background Questionsmentioning

confidence: 99%

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma

Martino¹,

Lemoli

Girmenia

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT) worldwide. The safety and efficacy of reducing hospital stay for MM patients undergoing ASCT have been widely explored, and different outpatient models have been proposed. However, there is no agreement on the criteria for selecting patients eligible for this strategy as well as the standards for their clinical management. On the basis of this rationale, the Italian Group for Stem Cell Transplantation (GITMO) endorsed a project to develop guidelines for the management of outpatient ASCT in MM, using evidence-based knowledge and consensus-formation techniques. An expert panel convened to discuss the currently available data on the practice of outpatient ASCT management and formulated recommendations according to the supporting evidence. Evidence gaps were filled with consensus-based statements. Three main topics were addressed: (1) the identification of criteria for selecting MM patients eligible for outpatient ASCT management; (2) the definition of standard procedures for performing outpatient ASCT (model, supportive care and monitoring during the aplastic phase); (3) the definition of the standard criteria and procedures for re-hospitalization during the aplastic phase at home. Herein, we report the summary and the results of the discussion and the consensus. INTRODUCTIONMultiple myeloma (MM) remains the leading indication for highdose chemotherapy and autologous stem cell transplantation (ASCT) worldwide 1,2 and the International Guidelines recommend that ASCT should be offered at some point during the treatment program for a medically fit patient. 3,4 High-dose melphalan (HDM) at 200 mg/m 2 is the standard conditioning for ASCT 5,6 and, today, the treatment should be considered a safe procedure with a very low transplant-related mortality (TRM). 7-9 The significant increase in the waiting lists generated concerns about the appropriate use of health care resources and, over the past years, some studies have investigated the safety, efficacy and potential cost advantages of reducing hospital stay for patients undergoing ASCT. [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] The ease of administering HDM, the relatively low extra-hematological toxicity and the short period of neutropenia 5,6 make MM patients ideal candidates for outpatient ASCT programs. Standardization of criteria for the outpatient ASCT policy is a relevant goal of the Italian hematology and transplant community and may facilitate comparison of retrospective and prospective data. The Italian Group for Stem Cell Transplantation (GITMO) endorsed a panel of 10 experts in the transplant field (MMa, RML, CG, LC, BB, MO, IL, MMo, GM and AO) to propose a consensus for the selection criteria and management of MM patients for ASCT procedure in the outpatient setting. METHODSA working group of 10 experts from 7 GITMO centers, with specific expertise in the field of ASCT, convened four times to: (a) identify common criteria for selecti...

show abstract

Improving stem cell mobilization strategies: future directions

Cited by 202 publications

References 133 publications

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

Stem cells: novel players in the treatment of erectile dysfunction

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma

Contact Info

Product

Resources

About